231722
Population Architecture using Genomics and Epidemiology (PAGE) -- from SNPs to GWAS and Beyond
Tuesday, November 9, 2010
: 3:15 PM - 3:30 PM
Dana Crawford, PhD
,
Department of Molecular Physiology & Biophysics, Vanderbilt, Nashville, TN
Gerardo Heiss, MD, PhD
,
Dept. of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC
Charles Kooperberg, PhD
,
Department of Biostatistics and Biomathematics, Fred Hutchinson Cancer Research Center, Seattle, WA
Loic Le Marchand, MD, PhD
,
Epidemiology Program, Cancer Research Center of Hawai‘i, Honolulu, HI
Tara Matise, PhD
,
Department of Genetics, Rutgers University, Piscataway, NJ
José Luis Ambite, PhD
,
Information Sciences Institute, University of Southern California, Marina del Rey, CA
Steven Buyske, PhD
,
Statistics Department, Rutgers University, Piscataway, NJ
Shelley Cole, PhD
,
Department of Genetics, Southwest Foundation for Biomedical Research, San Antonio, TX
Christopher Haiman, ScD
,
Zilkha Neurogenetic Institute, Keck School of Medicine, Los Angeles, CA
Teri Manolio, MD, PhD
,
Office of Population Genomics, National Human Genome Research Institute, Bethesda, MD
Kari North, PhD
,
Dept. of Epidemiology, UNC-Chapel Hill, Chapel Hill, NC
Ulrike (Riki) Peters, PhD, MPH
,
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
Marylyn Ritchie, PhD
,
Center for Human Genetics Research, Vanderbilt, Nashville, TN
Lucia Hindorff, PhD, MPH
,
Office of Population Genomics, National Human Genome Research Institute, Bethesda, MD
Jonathan Haines, PhD
,
Center for Human Genetics Research, Vanderbilt, Nashville, TN
. The PAGE Study
,
Center for Human Genetics Research, Vanderbilt, Nashville, TN
To date, genome-wide association studies (GWAS) have identified >2,500 SNPs associated with complex human diseases and traits at p<1.0 x10-5. Despite the success, most studies have been performed only in European-descent populations, and very little work has been performed in characterizing the associations in diverse populations. To fill this gap, the National Human Genome Research Institute funded the Population Architecture using Genomics and Epidemiology (PAGE) network, which consists of a Coordinating Center and four study sites that have access to the Multiethnic Cohort, the Women's Health Initiative, the National Health and Nutrition Examination Surveys, the Cardiovascular Health Study, Coronary Artery Risk Development in Young Adults Study, the Strong Heart Study, the Hispanic Community Health Study/Study of Latinos, and the Atherosclerosis Risk in Communities Study. The network's goals include generalizing GWAS-identified associations to diverse populations and identifying modifiers in these rich datasets that include both a breadth of phenotypes and exposures. To meet these goals, the network is genotyping ~200 single nucleotide polymorphisms (SNPs) per year in a subset of approximately 290,000 combined DNA samples that include Asian Americans, African Americans, European Americans, Hispanics, Native Hawaiians, and American Indians. After quality control, genotypes and individual-level and/or aggregate data will be deposited into dbGaP, a repository of GWAS and phenotypic data maintained by the National Center for Biotechnology Information (NCBI). The data will also be available on the PAGE custom browser available at www.pagestudy.org to ensure that investigators can access and mine these important data to better understand GWAS findings in a population-based setting.
Learning Areas:
Basic medical science applied in public health
Epidemiology
Other professions or practice related to public health
Public health biology
Public health or related research
Learning Objectives: Describe the PAGE network and their plans to disseminate data to other investigators.
Keywords: Genetics, Data/Surveillance
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I performed this research
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|